255 related articles for article (PubMed ID: 33866340)
21. Combined Utility of
Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
[TBL] [Abstract][Full Text] [Related]
22. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
23.
Sathekge M; Lengana T; Maes A; Vorster M; Zeevaart J; Lawal I; Ebenhan T; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):226-234. PubMed ID: 29101444
[TBL] [Abstract][Full Text] [Related]
24. Clinical parameters and nomograms for predicting lymph node metastasis detected with
Onal C; Ozyigit G; Oymak E; Guler OC; Hurmuz P; Tilki B; Reyhan M; Tuncel M; Akyol F
Prostate; 2021 Jul; 81(10):648-656. PubMed ID: 33949694
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy of
Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
[TBL] [Abstract][Full Text] [Related]
26.
Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
In Vivo; 2023; 37(3):1318-1322. PubMed ID: 37103095
[TBL] [Abstract][Full Text] [Related]
27. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
Bodar YJL; Veerman H; Meijer D; de Bie K; van Leeuwen PJ; Donswijk ML; van Moorselaar RJA; Hendrikse NH; Boellaard R; Oprea-Lager DE; Vis AN
BJU Int; 2022 Jun; 129(6):768-776. PubMed ID: 35166426
[TBL] [Abstract][Full Text] [Related]
28. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
29.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
30. Prospective Evaluation of
Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
[TBL] [Abstract][Full Text] [Related]
31. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
32. The role of histopathological and biochemical parameters for predicting metastatic disease on
Aydos U; Çetin S; Akdemir ÜÖ; Budak FÇ; Ateş SG; Koparal MY; Gönül İI; Gülbahar Ö; Sözen S; Atay LÖ
Prostate; 2021 Dec; 81(16):1337-1348. PubMed ID: 34516677
[TBL] [Abstract][Full Text] [Related]
33. Predictive significance of intraprostatic volumetric parameters derived from early and standard time 68Ga-PSMA PET/CT images in newly diagnosed prostate cancer patients.
Erdogan EB; Tekce E; Koca S; Aslan N; Toluk O; Aydin M
Nucl Med Commun; 2024 Jul; 45(7):629-641. PubMed ID: 38835183
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of two-time point [
Weitzer F; Pernthaler B; Plhak E; Riedl R; Aigner RM
Sci Rep; 2023 May; 13(1):8297. PubMed ID: 37217532
[TBL] [Abstract][Full Text] [Related]
35. Role of
Can C; Gündoğan C; Yildirim OA; Poyraz K; Güzel Y; Kömek H
Hell J Nucl Med; 2021; 24(1):25-35. PubMed ID: 33866336
[TBL] [Abstract][Full Text] [Related]
36.
Liu C; Liu T; Zhang N; Liu Y; Li N; Du P; Yang Y; Liu M; Gong K; Yang X; Zhu H; Yan K; Yang Z
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1852-1861. PubMed ID: 29717333
[TBL] [Abstract][Full Text] [Related]
37. Ability of
Yi N; Wang Y; Zang S; Yang L; Liu H; Sun H; Wang L; Wang F
Cancer Med; 2023 Mar; 12(6):7140-7148. PubMed ID: 36519688
[TBL] [Abstract][Full Text] [Related]
38. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
39.
Koerber SA; Utzinger MT; Kratochwil C; Kesch C; Haefner MF; Katayama S; Mier W; Iagaru AH; Herfarth K; Haberkorn U; Debus J; Giesel FL
J Nucl Med; 2017 Dec; 58(12):1943-1948. PubMed ID: 28619734
[No Abstract] [Full Text] [Related]
40. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
Meyrick DP; Asokendaran M; Skelly LA; Lenzo NP; Henderson A
Nucl Med Commun; 2017 Nov; 38(11):956-963. PubMed ID: 28922335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]